公开(公告)号：US11535611B2

公开(公告)日：2022-12-27

申请号：US16955926

申请日：2018-12-19

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgård ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl ,  Mauro Marigo

IPC: C07D401/14 ,  C07D405/14

Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

公开(公告)号：US20210047342A1

公开(公告)日：2021-02-18

申请号：US16916681

申请日：2020-06-30

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Erhad Ascic ,  Mauro Marigo ,  Laurent David

IPC: C07D495/04

Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

公开(公告)号：US20210015794A1

公开(公告)日：2021-01-21

申请号：US17060796

申请日：2020-10-01

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Karsten Juhl ,  Mauro Marigo ,  Paulo Jorge Vieira Vital ,  Mikkel Jessing ,  Morten Langgård ,  Lars Kyhn Rasmussen ,  Carl Martin Sebastian Clementson

IPC: A61K31/4162 ,  C07D471/04 ,  A61K31/4745 ,  C07D413/04

Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

公开(公告)号：US20210009571A1

公开(公告)日：2021-01-14

申请号：US16955926

申请日：2018-12-19

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgârd ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl ,  Mauro Marigo

IPC: C07D405/14 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

公开(公告)号：US20190352302A1

公开(公告)日：2019-11-21

申请号：US16424585

申请日：2019-05-29

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgård ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl ,  Mauro Marigo

IPC: A61K31/502 ,  C07D471/04 ,  C07D519/00 ,  C07D487/04 ,  A61P25/28 ,  A61P25/00 ,  A61P25/18 ,  A61P25/16

Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

公开(公告)号：US10045974B2

公开(公告)日：2018-08-14

申请号：US15524546

申请日：2015-11-09

Applicant: H. Lundbeck A/S

Inventor： Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo

IPC: C07D401/12 ,  A61K31/4439 ,  C07D417/12 ,  C07D413/12

Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.

公开(公告)号：US20180186769A1

公开(公告)日：2018-07-05

申请号：US15848013

申请日：2017-12-20

Applicant: H. Lundbeck A/S

Inventor： Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo

IPC: C07D401/12 ,  A61P25/28

CPC classification number: C07D401/12 ,  A61P25/28

Abstract: The invention provides amidine compounds of Formula I for the treatment of neurodegenerative or cognitive diseases, including Alzheimer's Disease.

公开(公告)号：US20180000786A1

公开(公告)日：2018-01-04

申请号：US15637920

申请日：2017-06-29

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Karsten Juhl ,  Mauro Marigo ,  Paulo Jorge Vieira Vital ,  Mikkel Jessing ,  Morten Langgård ,  Lars Kyhn Rasmussen ,  Carl Martin Sebastian Clementson

IPC: A61K31/4162 ,  C07D413/04 ,  A61K31/4745 ,  C07D401/04 ,  C07D305/06

CPC classification number: A61K31/4162 ,  A61K31/4745 ,  C07D305/06 ,  C07D401/04 ,  C07D413/04 ,  C07D471/04

Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

公开(公告)号：US20170340618A1

公开(公告)日：2017-11-30

申请号：US15524565

申请日：2015-11-09

Applicant: H. Lundbeck A/S

Inventor： Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo

IPC: A61K31/4439 ,  A61K31/506 ,  A61K31/444 ,  A61K31/497 ,  C07D413/12 ,  C07D401/12

CPC classification number: A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/506 ,  C07D401/12 ,  C07D413/12

Abstract: The present invention is directed to compounds of Formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.

公开(公告)号：US20170319564A1

公开(公告)日：2017-11-09

申请号：US15524546

申请日：2015-11-09

Applicant: H. Lundbeck A/S

Inventor： Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo

IPC: A61K31/4439 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12

CPC classification number: A61K31/4439 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12

Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.